Leading Edge 2020 Issue 1

www.alphalabs.co.uk 7 Printed on Recycled Paper Many laboratories are using the fCAL turbo on main stream clinical chemistry analysers (Abbott, Beckman, Roche and Siemens). There are also stand-alone options available which give laboratories the flexibility to choose how and where they want to run their assays. All sites in the UK are using the assay in conjunction with the CALEX extraction device as this offers the best workflow solution in today’s busy laboratories. Faecal Pancreatic Elastase Building on the success of the fCAL turbo assay, BÜHLMANN is launching its new fPELA assay for faecal pancreatic elastase. This will enable patients and pathways to benefit from the same workflow improvements that calprotectin has. With protocols available for many standard clinical chemistry analysers the BÜHLMANN fPELA is set to revolutionise faecal elastase testing. Pancreatic Insufficiency Pancreatic insufficiency is the reduction of production or transportation of the pancreatic enzymes. This results in the inability to properly digest fats, proteins or carbohydrates. It causes patients to suffer from a range of gastric symptoms including abdominal pain, weight loss, diarrhoea and loss of appetite. These symptoms can be confused with a variety of other gastric complaints; so performing a simple stool test to determine the level of pancreatic elastase helps with the diagnosis of this condition. Clinicians then just need to determine the cause…… Pancreatic insufficiency really is just another symptom but the cause is almost always pathogenic, resulting from conditions such as chronic pancreatitis, cystic fibrosis, diabetes mellitus, Crohn’s disease, pancreatic cancer, as well as a variety of other conditions. Pancreatic elastase is fairly stable in stool samples and so the levels of this are used as a marker to determine pancreatic activity as a whole. Multiple Assays from a Single Sample Extraction The new BÜHLMANN fPELA assay utilises the same CALEX extraction device as the fCAL turbo calprotectin assay, so it is possible to run both tests from a single tube. The CALEX is loaded straight onto the analysers without further diluting or decanting of the sample. Fast Turnaround With a time to first result of 10 minutes and further results following every few seconds thereafter, it is certainly one of the fastest faecal elastase assays available. Combine this with random access and no requirement for specific batch sizes you can easily see how this can improve the elastase service that is provided to clinicians, helping to quickly diagnose and support patients with pancreatic insufficiency. The assay has a standard range of 10 – 500µg/g, although the sample can be diluted to give values up to 5000µg/g if you want to find the best functioning pancreas! There is no interference with the results from Pancreatic Enzyme Replacement Treatments (PERT), so there is no need for patients to alter their therapy/diet before a test. Calibration is stable for around two months and reagents have an open on-board stability of about 2 months. The kits contain enough material for approximately 100 tests, however, this will be analyser dependent. Data from historic NEQAS samples shows the new BÜHLMANN fPELA gives comparable results to the current ELISA based methods [Figure 2] If you would like to evaluate the new BÜHLMANN fPELA Faecal Pancreatic Elastase assay then please contact senior product manager Amanda Appleton (aappleton@ alphalabs.co.uk) or your local Key Account Manager who can arrange this for you. Find out more about the BÜHLMANN range of calprotectin assays and CALEX extraction device at www.calprotectin.co.uk Figure 2 : NEQAS data shows the new BÜHLMANN fPELA gives comparable results to the current ELISA based methods.